4.1. Study Design and Patients
Clinical samples were collected from two phase 2 studies of patients with moderate-to-severe HS [Serum was collected from all participants at baseline and Weeks 4 and 8 for proteomic analysis. Availability of skin biopsy samples for transcriptomic analysis was limited to 12 sample pairs (15 mg povorcitinib once daily [QD], 